2019
Long-term outcomes in elderly patients (pts) from IMvigor210: Atezolizumab (atezo) in metastatic urothelial cancer (mUC).
Balar A, Dreicer R, Loriot Y, Perez-Gracia J, Hoffman-Censits J, Petrylak D, Van Der Heijden M, Shen X, Ding B, Ramirez-Montagut T, Rosenberg J. Long-term outcomes in elderly patients (pts) from IMvigor210: Atezolizumab (atezo) in metastatic urothelial cancer (mUC). Journal Of Clinical Oncology 2019, 37: 394-394. DOI: 10.1200/jco.2019.37.7_suppl.394.Peer-Reviewed Original ResearchMetastatic urothelial cancerElderly ptsCR ratePD-L1 statusSingle-arm studyLong-term outcomesLong-term efficacyEvaluable ptsMedian OSEfficacy outcomesElderly patientsClinical outcomesUrothelial cancerClinical benefitPoor outcomeSubgroup analysisOverall populationChemotherapyOutcomesCisplatinAtezoAtezolizumabQ3wOSPatients
2008
Efficacy and safety of docetaxel in the elderly
Mohile S, Berenji F, Sahasrabudhe D, Morrow G, Petrylak D. Efficacy and safety of docetaxel in the elderly. Aging Health 2008, 4: 113-127. DOI: 10.2217/1745509x.4.2.113.Peer-Reviewed Original ResearchElderly patientsWeekly dosingSide effectsSafety of docetaxelPhase II studyCommon side effectsElderly cancer patientsIncidence of myelosuppressionMost side effectsSolid tumor malignanciesEffective chemotherapeutic agentSignificant age-related effectsDermatologic toxicitiesII studyAdverse eventsDosing schedulesHypersensitivity reactionsCancer patientsFluid retentionAge-related effectsDose reductionTreatment planCancer subtypesTumor malignancyChemotherapeutic agents